New U.S. Patent Allowance Granted To Axim® Biotechnologies For Anti-Microbial Compositions Comprising Cannabinoids

World News: . []

NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- (“AXIM Biotech,” “AXIM” or “the Company”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent (Application No. 16/293,136) on anti-microbial compositions comprising cannabinoids, specifically cannabigerol (CBG). The USPTO granted this patent allowance from AXIM’s patent application filed on March 5, 2019.

All products that AXIM has the opportunity to produce under this patent will be made using CBG, a strong anti-microbial agent. AXIM aims to utilize this patent in the development of products for the treatment of symptoms associated with fungal-related diseases, including tinea pedis, commonly known as athlete’s foot. AXIM intends to develop future products under this patent in an aerosol form and foot powder for easy application. Other products with different anti-microbial applications are also considered for development under this patent.

According to Grand View Research, the global antifungal drugs market is expected to reach by 2025, giving AXIM the opportunity to offer its unique products to a large market.

“We have recognized the importance of patents since our early days with our well-known patent on chewing gum as a delivery mechanism for all cannabinoids,” said John W. Huemoeller II, Chief Executive Officer of AXIM® Biotech. “We look forward to continuing to lead cannabis innovation with this patent and future patents as the industry advances both in market growth and legitimacy.”

Once granted this patent, AXIM will hold eight issued patents and 11 pending patent applications.

For more information about the company and its clinical product pipeline, please visit .

AXIM's flagship product, MedChew® with dronabinol, is planned to undergo a bioequivalence study in the near future to fast track through FDA as an alternative to approved Marinol. For more information, please visit www.AXIMBiotech.com.

888-759-0844

 

More news and information about AXIM Biotechnologies, Inc

Published By:

Globe Newswire: 14:00 GMT Thursday 8th August 2019

Published: .

Search for other references to "patent" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us